124 related articles for article (PubMed ID: 1776137)
1. Comparative study on the in vitro effectiveness of antithrombotic agents.
Pâques EP; Römisch J
Thromb Res; 1991 Oct; 64(1):11-21. PubMed ID: 1776137
[TBL] [Abstract][Full Text] [Related]
2. Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition.
Stone SR; Tapparelli C
J Enzyme Inhib; 1995; 9(1):3-15. PubMed ID: 8568565
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
4. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
Römisch J; Stöhr HA; Stauss H; Koschinsky R; Stüber W; Pâques EP
Thromb Haemost; 1994 Mar; 71(3):320-4. PubMed ID: 8029796
[TBL] [Abstract][Full Text] [Related]
7. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
9. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
[TBL] [Abstract][Full Text] [Related]
10. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
11. Current developments in antithrombotic therapy: the role of antithrombin agents.
Breddin HK
Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():1-8. PubMed ID: 12811005
[TBL] [Abstract][Full Text] [Related]
12. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Callas D; Bacher P; Iqbal O; Hoppensteadt D; Fareed J
Thromb Res; 1994 May; 74(3):193-205. PubMed ID: 8042188
[TBL] [Abstract][Full Text] [Related]
14. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
15. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
16. Thrombin inhibitors in acute coronary artery disease.
Vorchheimer DA; Fuster V
Eur Heart J; 2002 Aug; 23(15):1142-4. PubMed ID: 12127916
[No Abstract] [Full Text] [Related]
17. Direct thrombin inhibitors.
Maffrand JP
Nouv Rev Fr Hematol (1978); 1992; 34(6):405-19. PubMed ID: 1300540
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
19. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.
Ries UJ; Priepke HW; Hauel NH; Handschuh S; Mihm G; Stassen JM; Wienen W; Nar H
Bioorg Med Chem Lett; 2003 Jul; 13(14):2297-302. PubMed ID: 12824021
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
